Gilead officer Dickinson proposes $376K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Gilead Sciences, Inc. officer Andrew Dickinson reported a proposed sale of 3,000 common shares, with an aggregate market value of $376,200 and an approximate sale date of June 15, 2026. The shares were acquired from the issuer as performance shares. The notice lists August 29, 2024, as the plan adoption or instruction date under Rule 10b5-1. It also reports three earlier sales of 3,000 shares each: May 15, 2026, for $396,810; April 15, 2026, for $422,880; and March 16, 2026, for $432,690 in gross proceeds.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.